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Primary cutaneous follicle centre lymphoma (PCFCL) is a rare cutaneous B cell lymphoma in middle-age adults with
excellent prognosis. Here we present a case of a patient with a PCFCL in the form of a giant tumour of the scalp in
combination with a myeloproliferative neoplasm, JAK2V617F positive essential thrombocythaemia. This case may be
of interest because of the favourable outcome in spite of the large size of the PCFCL, the rare combination with
essential thrombocythaemia and because it contributes to discussion on the role of JAK2 mutation in such patients.
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Myeloproliferative neoplasmBackground
Lymphoproliferative neoplasms (LPN) are a heterogeneous
group of tumours of the lymphoreticular system that might
manifest themselves as extranodal lymphomas, localized in
organs or tissues. Primary cutaneous B-cell lymphoma is a
distinct type of extranodal lymphomas with a particular
clinicopathologic presentation [1]. Primary cutaneous
follicle centre lymphoma (PCFCL) is the most common
variant of cutaneous B-cell lymphomas, representing
about 18% of all primary cutaneous lymphomas [2].
PCFCL usually manifests itself as variably sized, solitary
or grouped erythematous lesions, localized in the head,
neck, trunk, and upper extremities or, as in our patient,
as multifocal lesions. Treatment almost always leads to
complete remission but cutaneous relapses may occur.
Essential thrombocythaemia (ET) is a clonal myelo-
proliferative neoplasm (MPN) and JAK2V617F muta-
tions are found in approximately 50% of ET patients.
Only a few cases of concomitantly occurring MPN and
LPN have been reported [3-8]. Laurenti et al. published* Correspondence: Yordanka.Tirefort@hcuge.ch
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chronic lymphocytic leukemia (CLL) and concomitant
MPN [9] but at present, no systematic analysis for
MPN-LPN disease association is available and under-
lying pathogenic mechanisms remain unclear. Here we
present a patient with ET and a giant PCFCL tumour
of the scalp treated with chemo- and radiotherapy.
Case presentation
A 56-year-old man with an unremarkable medical his-
tory developed a multinodular mass on the scalp reach-
ing 19 × 16 × 4 cm over 18 months (Figure 1). Similar
lesions appeared on the face. Skin biopsies showed a
dense and diffuse infiltrate throughout the dermis and
the subcutis of CD20, CD79a and Bcl-6 positive, CD10
and IRF4 negative, large lymphoid cells with a focal
nodular growth pattern (Figure 2), an image typical of
cutaneous follicle centre lymphoma with a diffuse growth
pattern. IgH/Bcl-2 rearrangements were not detected using
FISH. Cross-sectional PET/CT and MRI imaging did not
reveal any evidence of systemic spread of the lymphoma
except for a suspicious spinal lymph node on the right side
of the neck (Figure 3). According to ISCL/EORTC classifi-
cation of cutaneous lymphomas [1], a diagnosis of PCFCL,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Multinodular mass on the scalp (A) and spectacular response after the second chemotherapy course (B).
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other blood counts were normal. LDH was normal and
there was no splenomegaly. Bone marrow biopsy revealed a
moderate hypercellularity with a marked proliferation of
mature megakaryocytes with hyperlobulated nuclei, some-
times in loose clusters, without increase in reticulin fibres
(Figure 2). Quantitative real-time PCR showed that 24% of
the nucleated cells in the blood carried the JAK2V617F mu-
tation, while scalp biopsies were only weakly positive (<3%),
probably due to granulocyte contamination. Screening for
HIV, EBV, HBV and HCV was negative.
Treatment
Because of the exceptional size of the tumour, its loca-
tion and possible nodal involvement, the patient received
systemic chemotherapy consisting of 4 cycles of Rituxi-
mab combined with Cyclophosphamide, Adriamycin,
Vincristine and Prednisone every 21 days (R-CHOP-21)
followed by consolidation radiotherapy. After the second
R-CHOP cycle, we observed a spectacular response with
90% reduction of tumour mass (Figures 1B, 3E, 3F). At
the time of writing, 2 years after diagnosis, the patient is
still in remission. The chemotherapy did not induce a
remission of ET and platelet counts remained stable at
600 – 700 × 109/L at 17 months after the last cycle of
chemotherapy. Because the patient was without clinical
symptoms of ET, no treatment other than a low dose
prophylactic aspirin was given.
Discussion
We present herein a patient with PCFCL and a con-
comitant ET, two neoplasms of which the relation is still
under debate [3-8]. For instance, Palandri et al. reported
that 8 of 499 ET patients (1.6%) also suffered from LPN[6], while Rumi at al. found a 2.79-fold higher risk of de-
veloping LPN in patients with MPN than in the general
population [8]. Similarly, Vannucchi et al. found a sig-
nificantly increased risk of developing LPN in patients
with MPN harbouring the JAK2V617F mutation, that
varied from 2.7 fold for any LPN and ET, 4.2 fold for
any LPN and PV to 12 fold in case of CLL and both ET
and PV [7]. Because the JAK2V617F mutation was found
in 2 of 3 LPN examined, they suggested that MPN and
LPN might originate from a common lymphoid-myeloid
progenitor. However, other studies did not report JAK2
mutations in the majority of LPN which underlines that
JAK2V617F might only be one of the perhaps several
factors favouring the genetic instability that predisposes
to lymphoid and to myeloproliferative neoplasms as
well [3,10,11].
We have treated our patient with R-CHOP-21, which
led to complete remission of the PCFCL without
impacting the ET. This is reminiscent of the findings
of Laurenti et al. who found that the course of MPN
was not influenced by treating the coexisting CLL and
that treating the MPN with hydroxyurea or imatinib
did not impact the course of the LPN [9]. Although
Palandri et al. did not find an increase in thrombotic
events in their cohort of patients with concomitant ET
and LPN [6], conventional chemotherapy for lymph-
oma might increase this risk considerably [12]. In the
future, alternative treatment modalities, as those tar-
geting the JAK/STAT pathway, might be useful because
of their potential interest for treatment of both disor-
ders in MPN-LPN patients. Downstream targets of the
JAK2 pathway such as the signal transducer and acti-
vator of transcription (STAT) proteins, the Ras/Raf/




Figure 2 Histopatological fingings. Biopsy of the mass of the scalp showing a dense and diffuse dermal infiltrate with nodular growth pattern
(A) consisted of large atypical lymphocytes (H&E) (B), which are positive for CD20 (C) and Bcl6 (D) and negative for Bcl2 (E) on immunohistochemical
staining. Bone marrow biopsy showing a hypercellular bone marrow with proliferation of megakaryocytes with hyperlobulated nuclei, sometimes in loose
clusters (H&E) (F), positive for CD61 on immunohistochemical staining (G).
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are often overexpressed in lymphoma subtypes such as
primary mediastinal B-cell- and Hodgkin lymphoma
[13-15]. Whether this is also true for the patient’s
PCFCL is not known. Unfortunately, we have not been
able to test whether the JAK2V617F mutation in our
patient had led to a sustained activation of the JAK2pathway. If so, it would make sense to treat future
MPN-LPN patients with the drugs targeting oncogenic
JAK/STAT pathways that are currently under investi-
gation for the treatment of myeloid and lymphoid
neoplasms [16,17]. A recent phase I trial has already
demonstrated a potential efficacy of the JAK2/FLT3 in-




Figure 3 Radiological investigations showing the lesions before treatment and their evolution after the treatment. MRI at diagnosis (A),
(B); PET-CT at diagnosis (C), (D); PET-CT and MRI after 2 cycles of R-CHOP (E), (F).
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of the 31 patients enrolled with minimal haemato-
logical toxicity [18]. Furthermore, phase II studies of
SB1518 in patients with myelofibrosis [19,20] are now
ongoing and if successful, this would certainly provide
a rationale for its use in patients with concurring mye-
loid and lymphoid malignancies.
Conclusion
The present case is of interest because of the unusual
presentation of PCFCL as a giant tumour of the scalp
with multifocal lesions but nevertheless excellent evolu-
tion. To our knowledge, this is the first report of apatient with MPN, JAK2V617F positive ET, and PCFCL.
The standard R-CHOP-21 therapy was successful for the
PCFCL but this treatment did not influence the evolu-
tion of ET. In the future, therapies targeting JAK/STAT
pathways that have shown potential for treatment of
MPN as well as for lymphoma, may be considered an
alternative.
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